论文部分内容阅读
紫杉类药物的问世是乳腺癌化疗中一重要突破。赫赛汀是第一个应用于乳腺癌的分子靶向治疗药物,它对HER-2/neu阳性乳腺癌特别有效。心脏安全性评估显示,AT→CMF是目前早期乳腺癌辅助化疗最安全的蒽环类/紫杉类方案。在对转移性乳腺癌的联合治疗上,联合化疗是否比序贯单药化疗在生存上更有优势仍是个重要的争论话题。
The advent of taxanes is an important breakthrough in breast cancer chemotherapy. Herceptin is the first molecular targeted therapies for breast cancer and is particularly effective in HER-2 / neu-positive breast cancer. Cardiac safety assessment shows that AT → CMF is the safest anthracycline / taxane regimen for early breast cancer adjuvant chemotherapy. Whether or not combination chemotherapy is superior to sequential monotherapy in the treatment of metastatic breast cancer remains an important topic of debate.